UroGen Pharma Ltd. (URGN) Financials

URGN Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 252.6 million 385.0 million
March 31, 2026 253.7 million 377.9 million
Dec. 31, 2025 200.5 million 305.9 million
Sept. 30, 2025 185.0 million 300.5 million

URGN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -33.1 million 5.3 million
March 31, 2026 -45.4 million 4.6 million
Dec. 31, 2025 -38.3 million 3.1 million
Sept. 30, 2025 -42.4 million 3.0 million

URGN Net Income

No data available :(

URGN Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 108.0 million 188.7 million 7.4 million
March 31, 2026 141.6 million 189.5 million 5.6 million
Dec. 31, 2025 120.5 million 122.2 million 6.1 million
Sept. 30, 2025 127.0 million 122.1 million 7.8 million

URGN Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 50.4 million
March 31, 2026 50.2 million
Dec. 31, 2025 49.2 million
Sept. 30, 2025 48.1 million

URGN Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 60000 17.3 million 48.4 million -
March 31, 2026 54000 15.6 million 51.5 million -
Dec. 31, 2025 17000 14.3 million 39.3 million -
Sept. 30, 2025 87000 14.0 million 37.6 million -

URGN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 72.5 million 6.6 million
March 31, 2026 51.0 million 4.1 million
Dec. 31, 2025 37.8 million 3.3 million
Sept. 30, 2025 27.5 million 3.3 million

URGN Revenue by Segment
Graph available only for paid members. Upgrade to see it.

URGN

Price: $36.61

52 week price:
15.86
50.81

Earnings Per Share: -1.97 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 20983

Ebitda: -286000

Market Capitalization: 2.0 billion

Links: